辅助治疗在当前膀胱癌围手术期免疫治疗试验中的作用：一个合理的标准。

IF 5.6 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2025-05-23 DOI:10.1016/j.euf.2025.05.008

Guru P Sonpavde

{"title":"辅助治疗在当前膀胱癌围手术期免疫治疗试验中的作用：一个合理的标准。","authors":"Guru P Sonpavde","doi":"10.1016/j.euf.2025.05.008","DOIUrl":null,"url":null,"abstract":"None of the ongoing phase 3 trials are evaluating the impact of the adjuvant component of perioperative PD1/PDL1 inhibition combined with neoadjuvant chemotherapy for muscle-invasive bladder cancer. Biomarkers of benefit are not validated. Hence, omission of the adjuvant component cannot be supported. Prospective investigation is required to evaluate this question.","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard.\",\"authors\":\"Guru P Sonpavde\",\"doi\":\"10.1016/j.euf.2025.05.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"None of the ongoing phase 3 trials are evaluating the impact of the adjuvant component of perioperative PD1/PDL1 inhibition combined with neoadjuvant chemotherapy for muscle-invasive bladder cancer. Biomarkers of benefit are not validated. Hence, omission of the adjuvant component cannot be supported. Prospective investigation is required to evaluate this question.\",\"PeriodicalId\":12160,\"journal\":{\"name\":\"European urology focus\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2025.05.008\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2025.05.008","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

没有一项正在进行的3期试验评估围手术期PD1/PDL1抑制的辅助成分联合新辅助化疗对肌肉浸润性膀胱癌的影响。有益的生物标志物没有得到验证。因此，佐剂成分的遗漏是不支持的。评价这个问题需要前瞻性调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard.

None of the ongoing phase 3 trials are evaluating the impact of the adjuvant component of perioperative PD1/PDL1 inhibition combined with neoadjuvant chemotherapy for muscle-invasive bladder cancer. Biomarkers of benefit are not validated. Hence, omission of the adjuvant component cannot be supported. Prospective investigation is required to evaluate this question.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.